Data Sheet (Cat.No.T6829)

TargetMol

EPI-001

Chemical Properties



CAS No. : 227947-06-0

Formula: C21H27ClO5

Molecular Weight: 394.89

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	EPI-001 is an androgen receptor N-terminal domain antagonist with IC50 of ~6 μM and a selective PPAR-gamma modulator.
Targets(IC50)	Apoptosis,Androgen Receptor,PPAR
In vitro	EPI-001 blocks transactivation of the AR NTD, interacts with the AF-1 region, inhibits protein-protein interactions with AR, and reduces AR interaction with androgen-response elements on target genes. In LNCaP cells, EPI-001 inhibits both androgen-dependent and androgen-independent (OCM-induced) cell proliferation. [1] In LNCaP cells, EPI-001 also acts as a PPAR-gamma modulator to result in inhibition of androgen receptor expression and activity, which inhibits prostate cancer growth. [2]
In vivo	In male mice bearing CRPC LNCaP s.c. xenografts, EPI-001 (50 mg/kg, i.v.) blocks the androgen-axis and inhibits androgen-dependent tumor growth by reducing proliferation and increasing apoptosis. [1]
Cell Research	LNCaP cells are treated with bicalutamide (BIC) or EPI-001 for 1 hr before the addition of R1881 (0.1 nM) for 4 days. LNCaP cells are treated with OCM (50%) with, or without, EPI-001 for 3 days (serum-free, androgen-free, phenol red-free conditions).(Only for Reference)

Solubility Information

Solubility	H2O: < 1 mg/mL (insoluble or slightly soluble), DMSO: 55 mg/mL (139.28 mM),Sonication is recommended. Ethanol: 70 mg/mL (177.26 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.06 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.5324 mL	12.6618 mL	25.3235 mL
5 mM	0.5065 mL	2.5324 mL	5.0647 mL
10 mM	0.2532 mL	1.2662 mL	2.5324 mL
50 mM	0.0506 mL	0.2532 mL	0.5065 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Andersen RJ, et al. Cancer Cell. 2010, 17(6), 535-546.
Brand LJ, et al. Oncotarget. 2015, 6(6), 3811-3824.